Shire bags US nod for primary immunodeficiency drug
Shire’s immunology portfolio has been given a boost with US approval for Cuvitru for the treatment of primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body’s immune system is missing or failing.
Read More





